Danaher Co. (NYSE:DHR) Shares Bought by Cwm LLC

Cwm LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 5.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,034 shares of the conglomerate’s stock after buying an additional 1,122 shares during the quarter. Cwm LLC’s holdings in Danaher were worth $5,755,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Argus Investors Counsel Inc. boosted its position in Danaher by 4.2% during the fourth quarter. Argus Investors Counsel Inc. now owns 2,925 shares of the conglomerate’s stock worth $677,000 after purchasing an additional 119 shares in the last quarter. Valley National Advisers Inc. grew its stake in Danaher by 43.9% in the 4th quarter. Valley National Advisers Inc. now owns 423 shares of the conglomerate’s stock valued at $97,000 after acquiring an additional 129 shares during the last quarter. Strategic Blueprint LLC increased its holdings in Danaher by 4.2% during the 4th quarter. Strategic Blueprint LLC now owns 8,804 shares of the conglomerate’s stock valued at $2,037,000 after acquiring an additional 358 shares in the last quarter. Confluence Wealth Services Inc. raised its position in Danaher by 3.5% during the fourth quarter. Confluence Wealth Services Inc. now owns 1,930 shares of the conglomerate’s stock worth $446,000 after acquiring an additional 66 shares during the last quarter. Finally, Pinnacle Bancorp Inc. lifted its holdings in shares of Danaher by 25.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 300 shares of the conglomerate’s stock valued at $69,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In related news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,174 shares of company stock valued at $29,775,644. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Citigroup upped their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. SVB Leerink upped their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price target for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $276.88.

Danaher Trading Down 2.1 %

DHR stock traded down $5.66 during trading on Wednesday, reaching $263.31. 2,783,996 shares of the stock traded hands, compared to its average volume of 2,909,317. The business’s 50 day moving average price is $256.77 and its 200-day moving average price is $251.78. The firm has a market capitalization of $195.03 billion, a PE ratio of 44.63, a P/E/G ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.